Cover Image
市場調查報告書

全球巨細胞病毒性視網膜炎市場

Global Cytomegalovirus Retinitis Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 310402
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
全球巨細胞病毒性視網膜炎市場 Global Cytomegalovirus Retinitis Market 2014-2018
出版日期: 2014年08月13日 內容資訊: 英文 52 Pages
簡介

巨細胞病毒性視網膜炎是視網膜病毒造成的發炎,若不治療有可能有失明的危險。就算最初只有單眼症狀,不管的話也會蔓延到另一個眼睛。HIV陽性患者等免疫力降低的人會罹患此疾病。全球巨細胞病毒性視網膜炎市場,預計2013∼2018年以年複合成長率4.50%擴大。

本報告提供全球巨細胞病毒性視網膜炎市場相關調查、今後的成長預測、各地區趨勢、市場課題、機會及威脅,及主要供應商簡介彙整。

第1章 摘要整理

第2章 簡稱清單

第3章 本報告的範圍

第4章 市場調查方法

第5章 簡介

第6章 市場環境

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 各給藥途徑市場區隔

  • 全身
  • 眼球

第8章 各給藥形態市場區隔

  • 膠囊
  • 移植
  • 溶液
  • 片劑

第9章 Valcyte的市場評估

第10章 發病率和罹患率

第11章 各地區市場區隔

第12章 購買標準

第13章 市場成長的促進要素

第14章 促進要素與其影響

第15章 市場課題

第16章 促進要素的影響與課題

第17章 市場趨勢

第18章 趨勢與其影響

第19章 供應商環境

  • 競爭模式
    • 主要消息
    • 合併、收購
  • 市場佔有率分析
  • 其他值得注意的供應商

第20章 供應商分析

  • Hospira
  • Gilead Sciences
  • Roche
  • Shire

第21章 本系列的其他報告

圖表

目錄
Product Code: IRTNTR3926

About Cytomegalovirus Retinitis

Cytomegalovirus retinitis is a viral eye inflammation of the retina. The causative organism of this disease is cytomegalovirus, a herpes virus that attacks the photosensitive cells in the retina. This disease can lead to permanent blindness if left untreated. It affects one eye initially but spreads to the other eye if neglected. The virus is very commonly found in humans but stays dormant. It usually affects a person with weakened immune system such as HIV-positive patients. There are two forms of cytomegalovirus retinitis: indolent form and fulminant form. Some of the common symptoms of cytomegalovirus retinitis are blurred vision, seeing floaters, photophobia, and blind spots.

TechNavio's analysts forecast the Global Cytomegalovirus Retinitis market to grow at a CAGR of 4.50 percent over the period 2013-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Cytomegalovirus Retinitis market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various branded and generic drugs used for the treatment of cytomegalovirus retinitis. Capsules, implants, solutions, and tablets are the four dosage forms of the drugs used for the treatment of cytomegalovirus retinitis.

TechNavio's report, the Global Cytomegalovirus Retinitis market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Cytomegalovirus Retinitis market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • F. Hoffmann-La Roche
  • Gilead Sciences
  • Hospira
  • Shire

Other Prominent Vendors

  • Auritec Pharmaceuticals
  • Chimerix Pharmaceuticals
  • Isis Pharmaceuticals
  • pSivida
  • Sanofi

Market Driver

  • Presence of Unmet Needs

For a full, detailed list, view our report

Market Challenge

  • Lack of Approved Treatment Guidelines by the World Health Organization

For a full, detailed list, view our report

Market Trend

  • Increase in Combination Therapies

For a full, detailed list, view our report

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings
    • 03.2.1. Product Profiles

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Market Segmentation by Route of Administration

  • 07.1.1. Systemic
  • 07.1.2. Ocular

08. Market Segmentation by Dosage Form

  • 08.1.1. Capsule
  • 08.1.2. Implant
  • 08.1.3. Solution
  • 08.1.4. Tablet

09. Market Assessment of Valcyte

10. Rate of Incidence and Prevalence

11. Geographical Segmentation

12. Buying Criteria

13. Market Growth Drivers

14. Drivers and their Impact

15. Market Challenges

16. Impact of Drivers and Challenges

17. Market Trends

18. Trends and their Impact

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2013
  • 19.3. Other Prominent Vendors

20. Key Vendor Analysis

  • 20.1. Hospira
    • 20.1.1. Business Overview
    • 20.1.2. Business Segmentation
    • 20.1.3. Key Information
    • 20.1.4. SWOT Analysis
  • 20.2. Gilead Sciences
    • 20.2.1. Business Overview
    • 20.2.2. SWOT Analysis
  • 20.3. Roche
    • 20.3.1. Business Overview
    • 20.3.2. Business Segmentation
    • 20.3.3. Key Information
    • 20.3.4. SWOT Analysis
  • 20.4. Shire
    • 20.4.1. Business Overview
    • 20.4.2. Key Information
    • 20.4.3. SWOT Analysis

21. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Cytomegalovirus Retinitis Market 2013-2018 (US$ million)
  • Exhibit 3: Global Cytomegalovirus Retinitis Market Segmentation by Route of Administration
  • Exhibit 4: Global Cytomegalovirus Retinitis Market Segmentation by Dosage Form
  • Exhibit 5: Timeline of Valcyte in the US and EU
  • Exhibit 6: Quarterly Sales of Valcyte 2013 (US$ million)
  • Exhibit 7: Quarterly Sales of Valcyte in the US 2013 (US$ million)
  • Exhibit 8: Quarterly Sales of Valcyte in Europe 2013 (US$ million)
  • Exhibit 9: Global Cytomegalovirus Retinitis Market by Geographical Segmentation
  • Exhibit 10: Business Segmentation of Hospira Inc.
  • Exhibit 11: Business Segmentation of F. Hoffmann La Roche Ltd.
Back to Top